Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cancer Supportive Care Drugs Market Worth $23.5 Billion By 2022: Grand View Research, Inc. By: AB Newswire October 19, 2018 at 06:16 AM EDT Grand View Research, Inc. - Market Research And Consulting.According to report by Grand View Research, Inc. The global cancer supportive care drugs market size is expected to be valued at USD 23.5 billion by 2022.The market to be driven by large number of side-effects associated with cancer treatment, increasing uptake of biosimilars, and availability of effective treatment methods, including target specific and tailored treatments.The global cancer supportive care drugs market size is expected to be valued at USD 23.5 billion by 2022, as per a new report by Grand View Research, Inc., progressing at a CAGR of 1.8% during the forecast period. The market is anticipated to be driven by large number of side-effects associated with cancer treatment, increasing uptake of biosimilars, rising expenditure on healthcare, and availability of effective treatment methods, including target specific and tailored treatments.Chemotherapy and radiotherapy are traditional methods for cancer treatment with approximately four million people receiving chemotherapy every year. Supportive care products are essential to prevent and manage symptoms and side-effects of cancer and its treatment.Among major cancer types, lung and breast cancers are the most prominent cancer type with the highest demand for supportive care drugs.G-CSFs and ESAs therapeutic classes are witnessing a fundamental shift from biologics to biosimilars. The market for cancer pain, chemotherapy induced nausea and vomiting, and cancer induced bone diseases will grow significantly during the forecast period, due to new product launches and high unmet needs. The cancer pain market is estimated to witness a shift from opioids to non-opioids therapies. The shift will be backed by patent loss, high mortality, addiction, and major safety issues associated with narcotic agents.Full Research Report On Cancer Supportive Care Drugs Market Analysis: www.grandviewresearch.com/industry-analysis/cancer-supportive-care-drugs-marketFurther key findings from the report suggest: Some of the key players operating in this industry are Amgen, Johnson & Johnson, Merck, Roche, Helsinn Healthcare, Heron Pharma, and TesaroAmong EU5, Germany captured the second position in the global cancer support care drugs market. Japan is poised to witness the fastest growth over the forecast periodThe CINV drugs market will be propelled by widening base of patients, increasing adoption of chemotherapeutic drugs, and launch of new drug delivery approaches to improve patient complianceIn Europe, Zarzio has taken over its reference product Neupogen in terms of market shareLate stage pipeline products include non-opioids such as Tanezumab and HTX-011Newer immunotherapies directed against PD-1 ligands and PD-L1 proteins have shown to be more effective with a superior safety profileBrowse More Reports Of This Category By Grand View Research At: www.grandviewresearch.com/industry/pharmaceuticalsGrand View Research has segmented the global cancer supportive care drugs market based on drug class and treatment:Cancer Supportive Care Drugs Therapeutic Class Outlook (Revenue, USD Million, 2016 - 2022)G-CSFsESAsAntiemeticsBisphosphonatesOpioidsNSAIDs and othersCancer Supportive Care Drugs Regional Outlook (Revenue, USD Million, 2016 - 2022)U.S.U.K.FranceGermanyItalySpainJapanExplore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.About Grand View ResearchGrand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.For more information: www.grandviewresearch.comMedia ContactCompany Name: Grand View Research, Inc.Contact Person: Sherry James, Corporate Sales Specialist - U.S.A.Email: Send EmailPhone: 1-415-349-0058, Toll Free: 1-888-202-9519Address:28 2nd Street, Suite 3036 City: San FranciscoState: CaliforniaCountry: United StatesWebsite: www.grandviewresearch.com/industry-analysis/cancer-supportive-care-drugs-market Source: www.abnewswire.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Cancer Supportive Care Drugs Market Worth $23.5 Billion By 2022: Grand View Research, Inc. By: AB Newswire October 19, 2018 at 06:16 AM EDT Grand View Research, Inc. - Market Research And Consulting.According to report by Grand View Research, Inc. The global cancer supportive care drugs market size is expected to be valued at USD 23.5 billion by 2022.The market to be driven by large number of side-effects associated with cancer treatment, increasing uptake of biosimilars, and availability of effective treatment methods, including target specific and tailored treatments.The global cancer supportive care drugs market size is expected to be valued at USD 23.5 billion by 2022, as per a new report by Grand View Research, Inc., progressing at a CAGR of 1.8% during the forecast period. The market is anticipated to be driven by large number of side-effects associated with cancer treatment, increasing uptake of biosimilars, rising expenditure on healthcare, and availability of effective treatment methods, including target specific and tailored treatments.Chemotherapy and radiotherapy are traditional methods for cancer treatment with approximately four million people receiving chemotherapy every year. Supportive care products are essential to prevent and manage symptoms and side-effects of cancer and its treatment.Among major cancer types, lung and breast cancers are the most prominent cancer type with the highest demand for supportive care drugs.G-CSFs and ESAs therapeutic classes are witnessing a fundamental shift from biologics to biosimilars. The market for cancer pain, chemotherapy induced nausea and vomiting, and cancer induced bone diseases will grow significantly during the forecast period, due to new product launches and high unmet needs. The cancer pain market is estimated to witness a shift from opioids to non-opioids therapies. The shift will be backed by patent loss, high mortality, addiction, and major safety issues associated with narcotic agents.Full Research Report On Cancer Supportive Care Drugs Market Analysis: www.grandviewresearch.com/industry-analysis/cancer-supportive-care-drugs-marketFurther key findings from the report suggest: Some of the key players operating in this industry are Amgen, Johnson & Johnson, Merck, Roche, Helsinn Healthcare, Heron Pharma, and TesaroAmong EU5, Germany captured the second position in the global cancer support care drugs market. Japan is poised to witness the fastest growth over the forecast periodThe CINV drugs market will be propelled by widening base of patients, increasing adoption of chemotherapeutic drugs, and launch of new drug delivery approaches to improve patient complianceIn Europe, Zarzio has taken over its reference product Neupogen in terms of market shareLate stage pipeline products include non-opioids such as Tanezumab and HTX-011Newer immunotherapies directed against PD-1 ligands and PD-L1 proteins have shown to be more effective with a superior safety profileBrowse More Reports Of This Category By Grand View Research At: www.grandviewresearch.com/industry/pharmaceuticalsGrand View Research has segmented the global cancer supportive care drugs market based on drug class and treatment:Cancer Supportive Care Drugs Therapeutic Class Outlook (Revenue, USD Million, 2016 - 2022)G-CSFsESAsAntiemeticsBisphosphonatesOpioidsNSAIDs and othersCancer Supportive Care Drugs Regional Outlook (Revenue, USD Million, 2016 - 2022)U.S.U.K.FranceGermanyItalySpainJapanExplore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.About Grand View ResearchGrand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.For more information: www.grandviewresearch.comMedia ContactCompany Name: Grand View Research, Inc.Contact Person: Sherry James, Corporate Sales Specialist - U.S.A.Email: Send EmailPhone: 1-415-349-0058, Toll Free: 1-888-202-9519Address:28 2nd Street, Suite 3036 City: San FranciscoState: CaliforniaCountry: United StatesWebsite: www.grandviewresearch.com/industry-analysis/cancer-supportive-care-drugs-market Source: www.abnewswire.com
